Enveric Biosciences (ENVB) EPS (Diluted) Growth (3y) (2017 - 2026)
Enveric Biosciences (ENVB) EPS (Diluted) Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 61.64% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 18.44% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 36.83% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -26.90% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.81% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 88.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.25% |
| Dec 31, 2025 | 77.75% |
| Sep 30, 2025 | 65.45% |
| Jun 30, 2025 | 71.26% |
| Mar 31, 2025 | 92.20% |
| Dec 31, 2024 | 93.59% |
| Sep 30, 2024 | 86.73% |
| Jun 30, 2024 | 80.68% |
| Mar 31, 2024 | 87.00% |
| Dec 31, 2023 | 74.56% |
| Sep 30, 2023 | 68.18% |
| Jun 30, 2023 | 68.30% |
| Mar 31, 2023 | 73.16% |
| Dec 31, 2022 | 70.96% |
| Sep 30, 2022 | 37.84% |
| Jun 30, 2022 | 72.78% |
| Mar 31, 2022 | 7.84% |
| Dec 31, 2021 | 27.90% |
| Sep 30, 2021 | -28.63% |
| Jun 30, 2021 | 54.35% |